186 related articles for article (PubMed ID: 18266608)
41. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
[TBL] [Abstract][Full Text] [Related]
42. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
43. A mouse model for studying viscerotropic disease caused by yellow fever virus infection.
Meier KC; Gardner CL; Khoretonenko MV; Klimstra WB; Ryman KD
PLoS Pathog; 2009 Oct; 5(10):e1000614. PubMed ID: 19816561
[TBL] [Abstract][Full Text] [Related]
44. Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses.
Fernandez-Garcia MD; Meertens L; Chazal M; Hafirassou ML; Dejarnac O; Zamborlini A; Despres P; Sauvonnet N; Arenzana-Seisdedos F; Jouvenet N; Amara A
mBio; 2016 Feb; 7(1):e01956-15. PubMed ID: 26861019
[TBL] [Abstract][Full Text] [Related]
45. The yellow fever 17D virus as a platform for new live attenuated vaccines.
Bonaldo MC; Sequeira PC; Galler R
Hum Vaccin Immunother; 2014; 10(5):1256-65. PubMed ID: 24553128
[TBL] [Abstract][Full Text] [Related]
46. Biological characterization of plaque-size variants of yellow fever virus in mosquitoes and mice.
Miller BR; Adkins D
Acta Virol; 1988 May; 32(3):227-34. PubMed ID: 2902770
[TBL] [Abstract][Full Text] [Related]
47. Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3'non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut.
McElroy KL; Tsetsarkin KA; Vanlandingham DL; Higgs S
Am J Trop Med Hyg; 2006 Dec; 75(6):1158-64. PubMed ID: 17172386
[TBL] [Abstract][Full Text] [Related]
48. Mutagenesis analysis of T380R mutation in the envelope protein of yellow fever virus.
Huang YJ; Nuckols JT; Horne KM; Vanlandingham D; Lobigs M; Higgs S
Virol J; 2014 Mar; 11():60. PubMed ID: 24678844
[TBL] [Abstract][Full Text] [Related]
49. Genome Characterization of Yellow Fever Virus Wild-Type Strain Asibi, Parent to Live-Attenuated 17D Vaccine, from Three Different Sources.
Davis EH; Thompson JK; Widen SG; Barrett ADT
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372589
[TBL] [Abstract][Full Text] [Related]
50. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.
Dayan GH; Pugachev K; Bevilacqua J; Lang J; Monath TP
Viruses; 2013 Dec; 5(12):3048-70. PubMed ID: 24351795
[TBL] [Abstract][Full Text] [Related]
51. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP
J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637
[TBL] [Abstract][Full Text] [Related]
52. Yellow fever vaccination centers: concurrent vaccinations and updates on mosquito biology.
Arya SC; Agarwal N
Travel Med Infect Dis; 2012 Sep; 10(5-6):257-8. PubMed ID: 22613468
[TBL] [Abstract][Full Text] [Related]
53. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti.
Jirakanjanakit N; Khin MM; Yoksan S; Bhamarapravati N
Am J Trop Med Hyg; 1999 Oct; 61(4):672-6. PubMed ID: 10548309
[TBL] [Abstract][Full Text] [Related]
54. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
[TBL] [Abstract][Full Text] [Related]
55. Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses.
Colpitts TM; Cox J; Vanlandingham DL; Feitosa FM; Cheng G; Kurscheid S; Wang P; Krishnan MN; Higgs S; Fikrig E
PLoS Pathog; 2011 Sep; 7(9):e1002189. PubMed ID: 21909258
[TBL] [Abstract][Full Text] [Related]
56. Oral receptivity of Aedes aegypti from Cape Verde for yellow fever, dengue, and chikungunya viruses.
Vazeille M; Yébakima A; Lourenço-de-Oliveira R; Andriamahefazafy B; Correira A; Rodrigues JM; Veiga A; Moreira A; Leparc-Goffart I; Grandadam M; Failloux AB
Vector Borne Zoonotic Dis; 2013 Jan; 13(1):37-40. PubMed ID: 23199267
[TBL] [Abstract][Full Text] [Related]
57. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
[TBL] [Abstract][Full Text] [Related]
58. Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti.
Miller BR; Beaty BJ; Aitken TH; Eckels KH; Russell PK
Am J Trop Med Hyg; 1982 Nov; 31(6):1232-7. PubMed ID: 7149108
[TBL] [Abstract][Full Text] [Related]
59. New approaches for the standardization and validation of a real-time qPCR assay using TaqMan probes for quantification of yellow fever virus on clinical samples with high quality parameters.
Fernandes-Monteiro AG; Trindade GF; Yamamura AM; Moreira OC; de Paula VS; Duarte AC; Britto C; Lima SM
Hum Vaccin Immunother; 2015; 11(7):1865-71. PubMed ID: 26011746
[TBL] [Abstract][Full Text] [Related]
60. Dengue and yellow fever virus vectors: seasonal abundance, diversity and resting preferences in three Kenyan cities.
Agha SB; Tchouassi DP; Bastos ADS; Sang R
Parasit Vectors; 2017 Dec; 10(1):628. PubMed ID: 29284522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
